Takeda jumps into Humira space

May 21, 2014 4:44 PM

4 0

Takeda jumps into Humira space

The FDA announced a new contender in the ulcerative colitis and Crohn's disease treatment space: Takeda, which scored approval of its infusion drug Entyvio for adults with moderate-to-severe forms of both diseases. The drug is indicated for patients who have not had an adequate response to previous treatments.

The OK puts the drugmaker in the mix with injectable peers including AbbVie's blockbuster Humira, which accounted for 57% of the Illinois drugmaker's 2013 sales, and has already provided nearly $3 billion to its sales so far this year. Part of Humira's power is its ability to attract new indications...

Read more

To category page

Loading...